Cullinan Therapeutics Trial Met Primary Endpoint
The Phase III REZILIENT3 lung cancer trial showed significant improvements for patients using zipalertinib.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Do you trust biotech companies that pivot their primary business strategy while undergoing clinical trials?
Cullinan Therapeutics achieved its primary endpoint in the Phase III REZILIENT3 trial on September 13, 2026. The study demonstrated improved progression-free survival for patients treated with zipalertinib plus chemotherapy.
Why it matters
This clinical success strengthens the company’s transition toward a broader drug pipeline, including autoimmune disease research. The partnership with Taiho Pharmaceutical helps manage oncology development costs while freeing resources for further drug exploration.
The REZILIENT3 trial of 279 previously untreated patients achieved a 0.50 hazard ratio. Zipalertinib acts as a small-molecule tyrosine kinase inhibitor targeting EGFR exon 20 insertions.
The players
Cullinan Therapeutics
A biotech firm based in Cambridge, Massachusetts, that focuses on oncology and autoimmune disease research.
Taiho Pharmaceutical
A Japanese pharmaceutical company that maintains a strategic partnership with Cullinan to share oncology program costs.
The details
The treatment combination significantly outperformed the control group in delaying cancer progression. Cullinan Therapeutics continues to develop its pipeline, including the CD19xCD3 T-cell engager CLN-978 for autoimmune conditions.
Timeline
2024: Company renamed from Cullinan Oncology to Cullinan Therapeutics.
April 2026: FDA accepted the new drug application for zipalertinib.
13 September 2026: Phase III REZILIENT3 trial met its primary endpoint.
The Tech Race
This development marks a significant shift in the competitive landscape of targeted lung cancer therapies. By expanding beyond oncology into autoimmune treatments, the company is diversifying its technology platform to reduce reliance on single-disease markets.
This result suggests a potential new treatment option for lung cancer patients with specific EGFR mutations. Future access to zipalertinib will depend on final regulatory approvals and the establishment of clinical availability.
The takeaway
The successful trial outcome validates the company's dual focus on oncology and autoimmune drug development. Investors and patients should monitor the end-of-year pipeline updates as the firm pivots its long-term strategy.
What happens next
The company expects to share readouts for its autoimmune disease drug pipeline by the end of 2026.
Further reading
Learn more about the latest developments in the field of Biotech.
Source note: This article includes information reported by Thepharmaletter.
Live Poll
Do you trust biotech companies that pivot their primary business strategy while undergoing clinical trials?
